List of Excipients in Branded Drug THAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	THAM	tromethamine	0409-1593	ACETIC ACID
Hospira Inc	THAM	tromethamine	0409-1593	WATER

THAM Excipient Strategy and Commercial Opportunities in Pharmaceutical Formulation

Last updated: September 24, 2026

THAM, or tromethamine, is both a marketed intravenous drug and a widely used pharmaceutical buffer. Its strongest commercial opportunity is not a new systemic medicine. It is high-quality, formulation-grade tromethamine for injectable, biologic, ophthalmic, topical, and oral products where formulators need pH control without adding sodium or chloride. The commercial barriers are regulatory classification, impurity control, extractables and leachables, supply reliability, and compatibility with active ingredients.

What is THAM and how is it used in pharmaceutical products?

THAM is the common name for tromethamine, also called tris(hydroxymethyl)aminomethane or TRIS. It is a weak organic base used as an alkalinizing agent and buffer.

The approved drug product is an aqueous intravenous solution generally identified as THAM Injection, containing 3.6% tromethamine. The product is used for selected forms of metabolic acidosis and for situations in which correction of acid-base imbalance is required without administering a sodium load.[1]

Attribute	THAM profile
Chemical name	Tromethamine; tris(hydroxymethyl)aminomethane
Common abbreviation	THAM or TRIS
Molecular formula	C4H11NO3
Molecular weight	Approximately 121.14 g/mol
Primary pharmaceutical role	Buffer and alkalinizing agent
Approved drug form	Sterile intravenous aqueous solution
Typical marketed strength	3.6% w/v
Route	Intravenous
Regulatory category	Active drug in THAM Injection; excipient or processing aid in other products
Biosimilar relevance	None
Generic competition	Possible through abbreviated or ANDA pathways, subject to product status and listing

THAM has a useful pH range near physiological conditions. Its buffering behavior is attractive in formulations that require pH adjustment without introducing high concentrations of sodium, potassium, phosphate, or chloride.

What excipient functions does tromethamine provide?

Tromethamine can perform several formulation functions, but its regulatory status depends on concentration, route, and intended use.

Buffering agent

THAM is used to stabilize formulation pH during manufacturing, storage, and administration. It can be paired with an acid such as hydrochloric acid to establish a target pH.

For injectable products, the buffer system must be evaluated for:

• pH drift over shelf life
• osmolality and tonicity
• precipitation risk
• interaction with the active pharmaceutical ingredient
• container compatibility
• sterilization impact
• local tolerability after administration

Alkalinizing agent

At sufficient concentrations, THAM is not merely a passive excipient. It can have a systemic pharmacologic effect. This distinction is important for injectable products, particularly when the amount administered is clinically meaningful.

A formulation using a low concentration of THAM as a pH adjuster may be regulated as an excipient function. A product using THAM to correct acidosis or alter systemic acid-base balance may be treated as a drug product in its own right.

pH adjuster

THAM can adjust acidic formulations into a target pH range. This use is relevant to biologics, vaccines, peptides, ophthalmic solutions, and topical products.

The principal benefit is the ability to adjust pH while limiting sodium content. That advantage is strongest in products where sodium burden affects patient suitability, formulation stability, or label positioning.

Stabilizing buffer for biologics

Tromethamine is used in some protein and antibody formulations as part of a buffer system. Its use can affect:

• aggregation
• deamidation
• oxidation
• subvisible particle formation
• adsorption to container surfaces
• freeze-thaw stability
• lyophilization behavior

THAM should not be selected solely because it produces a target pH. Buffer identity can affect protein conformation and degradation pathways. A development program should compare tromethamine with histidine, phosphate, citrate, acetate, and other candidate systems under accelerated and real-time conditions.

What THAM formulations are commercially attractive?

The most attractive opportunities are specialized formulations that require low-sodium buffering, high purity, or ready-to-use sterile presentation.

Injectable and infusion formulations

Parenteral products are the highest-value application because they require validated pharmaceutical-grade material, tight impurity specifications, and extensive supplier qualification.

Commercial opportunities include:

• ready-to-use sterile THAM solutions
• concentrated buffer products for hospital compounding
• premixed infusion products
• low-sodium alkalinizing formulations
• specialty products for intensive-care and renal-care settings
• custom buffer systems for injectable drugs

The main limitation is competition from established buffer systems and the regulatory burden associated with parenteral products.

Biologics and peptide formulations

Biologic developers may use tromethamine in liquid or lyophilized products where phosphate or citrate creates stability or compatibility problems. Potential target products include:

• monoclonal antibodies
• recombinant proteins
• peptide drugs
• vaccines
• cell and gene therapy ancillary formulations
• long-acting injectable products

A supplier can differentiate through low bioburden grades, low endotoxin specifications, validated sterilization options, and documentation suitable for biologics manufacturing.

Ophthalmic products

Tromethamine can be used in ophthalmic solutions and suspensions to control pH. Commercial potential exists in:

• preservative-free multidose systems
• ophthalmic suspensions
• anti-inflammatory eye drops
• antibiotic and antiviral ophthalmics
• products with narrow pH stability windows

Ophthalmic use requires close control of particulate matter, microbial quality, osmolality, preservative compatibility, and ocular tolerability.

Topical and transdermal products

Tromethamine can function as a pH modifier or neutralizing agent in creams, gels, lotions, and emulsions. It may also interact with acidic polymers and affect viscosity or release.

The opportunity is larger in specialty dermatology than in ordinary personal-care products because pharmaceutical developers pay more for validated supply and regulatory support.

Oral and liquid formulations

Tromethamine can be used in oral liquids and suspensions, although taste, pH, solubility, and gastrointestinal tolerability limit the opportunity. It is more commercially relevant in products where a specific pH is needed for stability or preservative performance.

How should companies design a THAM excipient strategy?

A successful strategy should treat tromethamine as a formulation component with pharmacological and regulatory implications, not as an interchangeable commodity.

Select the right grade

A supplier portfolio should separate:

Grade	Primary customer	Key requirements
General pharmaceutical grade	Oral and topical manufacturers	Identity, assay, impurities, residual solvents
Injectable grade	Parenteral manufacturers	Endotoxin, bioburden, particulate control, validated manufacturing
Biologics grade	Protein and peptide developers	Low trace metals, low peroxide burden, stability data
Sterile grade	Ready-to-use products	Sterilization validation, container integrity, sterility assurance
Research grade	Early development and laboratories	Flexible packaging and smaller quantities

The quality system should align with USP-NF, Ph. Eur., or other applicable compendial requirements. A supplier without a strong change-control and traceability system will face difficulty entering regulated injectable markets.[2]

Control impurity and contamination risk

The critical quality profile includes:

• assay
• related substances
• water content
• residual solvents
• elemental impurities
• microbial limits
• endotoxins
• particulate matter
• bioburden
• container-derived contaminants

Because tromethamine contains an amine group, manufacturers should assess the presence of nitrite, nitrate, and other potentially reactive impurities in the manufacturing process and formulation environment. The assessment should be product-specific and integrated into the sponsor’s nitrosamine risk-management program where relevant.[3]

Build compatibility data

A commercial excipient supplier can create significant value by supplying application data rather than only a certificate of analysis.

Useful data packages include:

• pH-buffer capacity curves
• osmolality contribution by concentration
• compatibility with common APIs
• freeze-thaw results
• autoclave and terminal sterilization studies
• lyophilization cycle data
• protein aggregation data
• adsorption studies
• extractables and leachables information
• stability in glass, cyclic olefin polymer, and multilayer plastic containers

This data can shorten formulation development and improve customer retention.

What is the regulatory status of THAM as an excipient?

THAM has two distinct regulatory profiles.

THAM as an active ingredient

In THAM Injection, tromethamine is the active ingredient. The product is regulated as a prescription drug, and the label includes dosing, warnings, contraindications, administration instructions, and monitoring requirements.[1]

The active-drug status means that a sponsor cannot assume that a formulation containing tromethamine will be treated as an ordinary excipient product. The agency will assess dose, route, exposure, intended function, and pharmacologic effect.

THAM as an inactive ingredient

In other products, tromethamine may be used as a buffer or pH adjuster. The FDA Inactive Ingredient Database is a useful starting point for determining whether prior use exists at a particular route and dosage form.[4]

Prior inactive-ingredient use does not eliminate the need for product-specific safety and quality assessments. A proposed concentration, route, patient population, or dosage form may exceed the established precedent.

FDA Orange Book status

The Orange Book is relevant to approved drug products and therapeutic-equivalence determinations, not to excipient ownership generally.[5] THAM’s commercial opportunity as a raw material is therefore not dependent on Orange Book exclusivity.

For a specific THAM Injection product, commercial teams should verify:

• current NDA or ANDA status
• whether the product is actively marketed
• whether the product appears in the current Orange Book
• whether any listed patents remain relevant
• whether a generic applicant has filed a Paragraph IV certification
• whether the reference product has been discontinued or withdrawn

What patents protect THAM and THAM-based formulations?

The underlying THAM molecule is an old chemical entity. Basic composition-of-matter patent protection is not a practical barrier for modern commercial entry.

The relevant intellectual-property risks are more likely to arise from:

• a specific injectable concentration
• a defined pH range
• a particular buffer combination
• a biologic formulation containing THAM
• a lyophilized cake or reconstitution system
• a container-closure configuration
• a sterilization process
• a manufacturing process
• a combination product
• a method of treating a defined acid-base disorder

Patent-strength assessment

IP category	Expected strength for THAM commercial strategy
THAM composition of matter	Very weak because of molecule age
Generic THAM raw material	Usually weak unless manufacturing process is differentiated
THAM Injection formulation	Potentially limited, depending on claims and patent age
Biologic formulation containing THAM	Moderate to strong if claims are narrow and data-supported
Sterile manufacturing process	Moderate where process parameters are difficult to design around
Packaging and delivery system	Moderate, particularly for ready-to-use or dual-chamber products
Method-of-use claims	Product-specific and vulnerable to design-around
Trade secrets	Potentially important for impurity control and scale-up

Patent analysis should distinguish between patents covering THAM itself and patents covering a customer’s finished drug formulation. A THAM supplier generally has greater commercial protection from quality systems, regulatory files, validated manufacturing, and customer qualification than from broad compound patents.

When does THAM lose exclusivity, and what generic-entry risks exist?

THAM does not have a meaningful modern exclusivity cliff comparable to a recently approved small-molecule drug. The molecule and its principal medical use have been known for decades.

The relevant entry scenarios are:

1. A generic injectable manufacturer develops a therapeutically equivalent THAM Injection product.
2. A hospital or institutional buyer substitutes a competing product after supplier qualification.
3. A formulation sponsor replaces THAM with histidine, phosphate, citrate, acetate, or another buffer.
4. A biologic sponsor protects a THAM-containing formulation through a product-specific patent.
5. A supplier enters with a lower-cost nonsterile pharmaceutical grade and later expands into sterile supply.

Paragraph IV risk is most relevant to a listed reference drug product, not to THAM as a bulk excipient. A generic applicant would need to evaluate any active Orange Book patents and exclusivity associated with the specific reference product. Because the principal THAM product is old, the larger commercial risk is approval, manufacturing economics, and hospital purchasing rather than a new patent challenge.

Which companies are competing in the THAM market?

Competition exists at three levels:

Finished drug manufacturers

Companies may market tromethamine injection under a brand, authorized generic, or generic label. Product availability can change because of manufacturing decisions, shortages, acquisitions, or hospital-contract dynamics.

Pharmaceutical raw-material suppliers

These companies compete on:

• compendial compliance
• batch consistency
• global supply
• audit readiness
• lead time
• packaging
• regulatory documentation
• low endotoxin capability
• sterile filling partnerships

Alternative buffer suppliers

THAM competes indirectly with:

• histidine
• phosphate
• citrate
• acetate
• succinate
• tromethamine combinations
• amino-acid buffers
• proprietary buffer systems

The strongest competitive threat is often substitution rather than a direct THAM supplier. A customer can remove THAM from a formulation if another buffer provides comparable stability, tolerability, and manufacturability.

What licensing and partnership opportunities exist?

THAM itself is unlikely to generate substantial royalty value through basic molecule licensing. More practical opportunities include:

• co-development of THAM-containing biologic formulations
• supply agreements with minimum-volume commitments
• exclusive regional distribution
• sterile fill-finish partnerships
• custom buffer manufacturing
• regulatory-support packages for emerging-market registrations
• licensing of ready-to-use infusion products
• formulation platform agreements with injectable-drug developers

A supplier with validated sterile production can capture more value than a bulk-chemical supplier. The highest-value model is a qualified, documented, application-supported product that becomes embedded in a customer’s regulatory dossier.

How does THAM compare with competing pharmaceutical buffers?

Buffer	Advantages	Limitations
Tromethamine	Low sodium contribution; useful near physiological pH; injectable history	Can have pharmacologic effects; amine-related impurity assessment; compatibility must be demonstrated
Histidine	Common in biologics; useful near mildly acidic pH	May have limited capacity at neutral or alkaline pH
Phosphate	Familiar and inexpensive; strong regulatory precedent	Can precipitate with calcium or metals; may affect protein stability
Citrate	Effective acidic buffer; broad pharmaceutical use	Can complex metals and affect tolerability
Acetate	Simple and widely understood	Odor, tolerability, and pH-range limitations
Succinate	Useful for selected biologics	Less universal formulation precedent

THAM has its best position where sodium reduction, near-neutral buffering, or specific biologic stability outweighs the regulatory complexity of using an amine-based buffer.

What is the commercial outlook for THAM?

The market opportunity is specialized rather than mass-market. Revenue exposure is most attractive in:

• sterile injectable excipient supply
• biologic formulation support
• high-purity pharmaceutical grades
• low-endotoxin material
• ready-to-use buffer solutions
• hospital injectable products
• custom formulation services

Raw THAM is likely to remain price-competitive. Margin expansion requires differentiation through documentation, quality, supply assurance, sterile presentation, and technical support.

A practical commercialization plan should prioritize three products:

1. A compendial, nonsterile pharmaceutical-grade tromethamine for formulation development and oral or topical use.
2. A low-endotoxin, injectable-grade product supported by extensive quality documentation.
3. A ready-to-use sterile THAM buffer or infusion product for customers seeking reduced manufacturing complexity.

Key Takeaways

• THAM is tromethamine, a weak organic base used as both an active drug and a pharmaceutical buffer.
• The strongest opportunity is in injectable, biologic, ophthalmic, and specialty topical formulations.
• THAM can reduce sodium burden but may have pharmacologic significance at higher doses.
• The molecule has little practical composition-of-matter patent value because it is old.
• Commercial protection is more likely to come from quality systems, customer qualification, process know-how, and application data.
• Generic-entry risk for THAM Injection is driven primarily by regulatory approval, manufacturing economics, and market access.
• The principal technical risks are pH drift, protein compatibility, endotoxin control, sterilization, container interaction, and impurity management.
• A supplier should compete on validated pharmaceutical quality and formulation support rather than bulk chemical price alone.

FAQs

Is THAM the same as tromethamine and TRIS?

Yes. THAM, tromethamine, tris(hydroxymethyl)aminomethane, and TRIS refer to the same chemical, although grade, purity, and intended use may differ.

Can THAM be used in biologic drug products?

Yes. THAM can be used in liquid and lyophilized biologic formulations, subject to product-specific stability, compatibility, safety, and regulatory evaluation.

Is THAM a buffer or an active pharmaceutical ingredient?

It can be either. In THAM Injection, it is the active pharmaceutical ingredient. In another product, it may function as a buffer or pH adjuster.

Does THAM create a sodium-free formulation?

THAM can reduce or eliminate sodium added through the buffering system, but the finished product may still contain sodium from other ingredients, the active ingredient, or manufacturing materials.

Is THAM suitable for sterile injectable manufacturing?

Yes, provided the material meets the applicable pharmaceutical quality requirements and the finished product satisfies sterility, endotoxin, particulate, container-closure, stability, and process-validation requirements.

References

1. U.S. Food and Drug Administration. (n.d.). THAM (tromethamine injection) prescribing information. DailyMed.

2. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Tromethamine monograph. USP-NF.

3. U.S. Food and Drug Administration. (2023). Nitrosamine impurities in human drugs: Guidance for industry. FDA.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.